An innovative intervention for the prevention of vaso-occlusive episodes in sickle cell disease

References

• Okomo U, Meremikwu MM. Fluid replacement therapy for acute episodes of pain in people with sickle cell disease. Cochrane Database Syst Rev. 2021;2021(7):CD005406. doi:10.1002/14651858.CD005406.pub5
   Google Scholar
• Tanhehco YC, Shi PA, Schwartz J. Transfusion therapy in sickle cell disease. Ann Blood. 2022;7(0):9. doi:10.21037/aob-21-67
   Google Scholar
• Peslak SA, Akins AB, Foxwell AM, et al. A novel, effective, and efficient strategy for treating sickle cell vaso-occlusive events in the infusion center setting. Blood Adv. 2023;410:410–413. doi:10.1182/bloodadvances.2022007307
   Google Scholar
• Gaartman AE, Sayedi AK, Gerritsma JJ, et al. Fluid overload due to intravenous fluid therapy for vaso-occlusive crisis in sickle cell disease: incidence and risk factors. Br J Haematol. 2021;194(5):899–907. doi:10.1111/bjh.17696
   PubMed Web of Science ®Google Scholar
• Howard J. Sickle cell disease: when and how to transfuse. Hematology Am Soc Hematol Educ Program. 2016;2016(1):625–631. doi:10.1182/asheducation-2016.1.625
   PubMed Web of Science ®Google Scholar
• Brandow AM, Carroll CP, Creary S, et al. American Society of Hematology 2020 guidelines for sickle cell disease: management of acute and chronic pain. Blood Adv. 2020;4(12):2656–2701. doi:10.1182/bloodadvances.2020001851.
   PubMed Web of Science ®Google Scholar
• McGann PT, Weyand AC. Lessons learned from the COVID-19 pandemic blood supply crisis. J Hosp Med. 2022;17(7):574–576. doi:10.1002/jhm.12843
   PubMed Web of Science ®Google Scholar
• Banks M, Shikle J. Hyperhemolysis syndrome in patients with sickle cell disease. Arch Pathol Lab Med. 2018;142(11):1425–1427. doi:10.5858/arpa.2017-0251-RS
   PubMed Web of Science ®Google Scholar
• Arzoun H, Srinivasan M, Sahib I, et al. Opioid use in patients with sickle cell disease during a vaso-occlusive crisis: a systematic review. Cureus. 2022;14(1):e21473. doi:10.7759/cureus.21473
   PubMed Web of Science ®Google Scholar
• Charache S, Terrin ML, Moore RD, et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the multicenter study of hydroxyurea in sickle cell anemia. N Engl J Med. 1995;332(20):1317–1322. doi:10.1056/NEJM199505183322001
   PubMed Web of Science ®Google Scholar
• Adams RJ, McKie VC, Hsu L, et al. Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial Doppler ultrasonography. N Engl J Med. 1998;339(1):5–11. doi:10.1056/NEJMoa050460.
   PubMed Web of Science ®Google Scholar
• Adams RJ, Brambilla D. Optimizing primary stroke prevention in sickle cell anemia (STOP 2) trial investigators. Discontinuing prophylactic transfusions used to prevent stroke in sickle cell disease. N Engl J Med. 2005;353(26):2769–2778.
   PubMed Web of Science ®Google Scholar
• Ware RE, Helms RW. Stroke With transfusions changing to hydroxyurea (SWiTCH). Blood. 2012;119(17):3925–3932. doi:10.1182/blood-2011-11-392340
   PubMed Web of Science ®Google Scholar
• DeBaun MR, Gordon M, McKinstry RC, et al. Controlled trial of transfusions for silent cerebral infarcts in sickle cell anemia. N Engl J Med. 2014;371(8):699–710. doi:10.1056/NEJMoa1401731
   PubMed Web of Science ®Google Scholar
• Ware RE, Davis BR, Schultz WH, et al. Hydroxycarbamide versus chronic transfusion for maintenance of transcranial Doppler flow velocities in children with sickle cell anaemia—TCD with transfusions changing to Hydroxyurea (TWiTCH): a multicentre, open-label, phase 3, non-inferiority trial. Lancet. 2016;387(10019):661–670. doi:10.1016/S0140-6736(15)01041-7
   PubMed Web of Science ®Google Scholar
• Lanzkron S, Carroll CP, Hill P, et al. Impact of a dedicated infusion clinic for acute management of adults with sickle cell pain crisis. Am J Hematol. 2015;90(5):376–380. doi:10.1002/ajh.23961v
   PubMed Web of Science ®Google Scholar
• Dick MH, Abdelgadir A, Kulkarni VV, et al. Comparing the safety and efficacy of L-glutamine, voxelotor, and crizanlizumab for reducing the frequency of vaso-occlusive crisis in sickle cell disease: a systematic review. Cureus. 2022;14(5):e24920. doi:10.7759/cureus.24920
   PubMed Web of Science ®Google Scholar
• Lanzkron S, Little J, Wang H, et al. Treatment of acute pain in adults with sickle cell disease in an infusion center versus the emergency department: a multicenter prospective cohort study. Ann Intern Med. 2021;174(9):1207–1213. doi:10.7326/M20-7171
   PubMed Web of Science ®Google Scholar
• Salinas Cisneros G, Thein SL. Recent advances in the treatment of sickle cell disease. Front Physiol. 2020;11:435. Published 2020 May 20. doi:10.3389/fphys.2020.00435
   PubMed Web of Science ®Google Scholar
• Ali MA, Ahmad A, Chaudry H, et al. Efficacy and safety of recently approved drugs for sickle cell disease: a review of clinical trials. Exp Hematol. 2020;92:11–18.e1. doi:10.1016/j.exphem.2020.08.008
   PubMed Web of Science ®Google Scholar
• Howard J, Ataga KI, Brown RC, et al. Voxelotor in adolescents and adults with sickle cell disease (HOPE): long-term follow-up results of an international, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Haematol. 2021;8(5):e323–e333. doi:10.1016/S2352-3026(21)00059-4.
   PubMedGoogle Scholar
• Purnell MC, Rayborn M. Novel hydration and nutritional strategies for sickle cell disease. EJHaem. 2020;1(1):230–234. doi:10.1002/jha2.9
   PubMedGoogle Scholar
• Carden MA, Fay ME, Lu X, et al. Extracellular fluid tonicity impacts sickle red blood cell deformability and adhesion. Blood. 2017;130(24):2654–2663. doi:10.1182/blood-2017-04-780635
   PubMed Web of Science ®Google Scholar
• Gaut D, Jones J, Chen C, et al. Outcomes related to intravenous fluid administration in sickle cell patients during vaso-occlusive crisis. Ann Hematol. 2020;99(6):1217–1223. doi:10.1007/s00277-020-04050-1
   PubMed Web of Science ®Google Scholar
• Mercadante S, Arcuri E, Santoni A. Opioid-induced tolerance and hyperalgesia. CNS Drugs. 2019;33(10):943–955. doi:10.1007/s40263-019-00660-0
   PubMed Web of Science ®Google Scholar